ClinicalTrials.gg
RecruitingNCT05979818BRIOUpdated Nov 19, 2026

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of Propranolol hydrochloride and Sintilimab in Non Small Cell Lung Cancer, Propranolol and Immune Checkpoint Inhibitors, sponsored by Second Xiangya Hospital of Central South University. Recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Second Xiangya Hospital of Central South University · Phase 1/2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 988 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
733rd of 1,597
118 · median 100
Started
2024
with 202 others
Phase 1/2
161 of 1,885
84 open now
Primary completion
2028-10
later than 803 of 987 live
Registered
1,171st of 1,885
by date

Among the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 733rd largest by planned enrollment of the 1,597 interventional ones that give a count, is one of 203 that started in 2024, is one of 161 in phase 1/2, reaches primary completion later than 803 of the 987 other live ones, and was the 1,171st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This study is a prospective multi-center Phase Ib/II clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta-adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Propranolol
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • β-adrenergic Antagonists
  • Emotional Distress
  • PD-1 Inhibitors
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign a written prior to any research-related procedure
  • Age ≥18 years and ≤ 75 years old
  • PS score of 0-1
  • Expected survival time ≥ 12 weeks
  • Patients with or cytologically confirmed non-localizable stage IIIB-IIIC, stage IV non-small cell lung cancer (International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancers, 8th edition). Patients with unresectable IIIB-IIIC include recurrent and primary unresectable (surgery and radical concurrent chemoradiotherapy), and stage IV includes primary or recurrent stage IV but without prior systemic therapy for advanced/ disease.
  • Chemotherapy and chemoradiotherapy are permitted as /adjuvant treatment as long as the treatment is completed at least 12 months prior to the diagnosis of advanced or metastatic disease
  • There must be no EGFR gene-sensitive mutation, ALK gene fusion or ROS1 gene fusion in non-squamous carcinoma
  • At least one imaging according to the criteria for the evaluation of the efficacy of solid tumors ( version 1.1). A lesion located in the field of exposure to previous radiotherapy is considered measurable if progression is confirmed (within 28 days prior to the first treatment)
  • Subjects with who are asymptomatic or whose symptoms have stabilized with local treatment are permitted to be enrolled, provided that the subject meets the following criteria:

    1. Have a measurable lesion outside the CNS.
    2. No CNS symptoms or no worsening of symptoms for at least 2 weeks.
  • Meet the following laboratory indicators (within 14 days before the first treatment):

    1. Blood routine examination: ≥ 1.5 x 10\^9/L; count ≥ 100 x 10\^9/L; level ≥ 9.0 g/dL (no blood transfusion or erythropoietin-dependent administration within 7 days).
    2. Liver function: total (TBIL) ≤ 1.5 × (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN in the absence of hepatic metastases; ALT or AST ≤ 5 × ULN in the case of patients with hepatic metastases.
    3. Renal function: serum creatinine (Cr) ≤1.5 times ULN or Cr clearance ≥60 mL/min ( formula), and urine routine test results show urine protein (UPRO) \<2+ or 24-hour urine protein quantification \<1g.
    4. Coagulation: (INR) ≤ 1.5 times ULN or Prothrombin Time (PT) ≤ 1.5 times ULN within 7 days prior to study treatment; if the subject is receiving anticoagulant therapy, as long as the PT is within the range of the anticoagulant drug
  • Heart function: the (NYHA) classification \< 3;(LVEF)≥ 50%; Baseline showed no PR interval lengthened or atrioventricular block
  • For female subjects of , a negative urine or serum pregnancy test should be obtained within 3 days prior to receiving the first dose of study drug (Day 1 of Cycle 1). If a negative urine pregnancy test result cannot be confirmed, a blood pregnancy test will be requested. Females not of childbearing potential are defined as being at least 1 year or having undergone surgical sterilization or hysterectomy; if conception is at risk, all subjects (male or female) are required to use with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the end-of-treatment administration of study drug (or 180 days after the end-of-study drug administration)

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in another interventional clinical study or receipt of another drug, unless participating in an observational clinical study
  • Prior exposure to any or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Systemic therapy with proprietary Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thiopeptides, interferons, interleukins, except those used locally for the control of hydrothorax or ascites) within 2 weeks prior to the first dose
  • Current use of oral or intravenous beta-blockers (e.g., atenolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, sotalol, etc.) cannot be safely switched to a non-beta-blocker
  • There are to the use of beta-blockers:

    1. to any of the components of the product.
    2. Bronchial asthma or risk of bronchospasm.
    3. Ketoacidosis and metabolic acidosis.
    4. Severe or symptomatic bradycardia (resting heart rate ≤55bpm), atrioventricular block (degrees II and III), sinus block, sick sinus node syndrome.
    5. Cardiogenic shock
    6. Right heart insufficiency due to pulmonary hypertension.
    7. Congestive heart failure (class III or IV).
    8. Hypotension (systolic blood pressure \< 100 mmHg).
    9. Prolonged fasting.
    10. Severe peripheral circulatory failure (e.g., gangrene).
    11. Symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma.
    12. Unstable angina or variant angina.
    13. Patients on rizatriptan benzoate.
    14. Severe (COPD)
    15. Uncontrolled type I or type II diabetes mellitus (glycosylated [] > 8.5 or fasting blood glucose > 160 mg/dl at screening).
    16. Current use or within the last 2 years of a non-dihydropyridine calcium channel blocker (NDCCB)
  • Hepatic encephalopathy, hepatorenal syndrome or class B or more severe cirrhosis
  • Tumor-related intestinal obstruction (within 3 months prior to the signing of the ) or history of inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis
  • Completion of palliative radiotherapy within 7 days prior to the first dose of study drug
  • With clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction
  • History of psychotropic substance abuse or addiction
  • Known hypersensitivity to the active ingredients or of the study drug
  • Known history of primary immunodeficiency or undergoing systemic therapy or any other form of therapy
  • Use of immunosuppressive drugs, excluding topical glucocorticoids by nasal, inhalational or other routes or physiological doses of systemic glucocorticoids (i.e., no more than 10 mg/day of prednisone or an equivalent dose of other glucocorticoids), or use of hormones for the prevention of contrast sensitization, within 4 weeks prior to the first dose of study treatment
  • Failure to recover adequately from any intervention-induced toxicity and/or complications (≤ grade 1 or baseline, excluding weakness or alopecia) prior to initiation of treatment
  • Receipt of live attenuated influenza vaccine within 4 weeks prior to the first dose of study treatment or planned for the duration of the study (inactivated injectable viral vaccine against seasonal influenza is permitted up to 4 weeks prior to the first dose; however, live attenuated influenza vaccine is not permitted)
  • Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment or anticipation of major surgery during study treatment; laparoscopic exploratory surgery within 2 weeks prior to the first dose of study treatment
  • Known symptomatic and/or carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the trial if they are clinically stable (no evidence of imaging progression for at least 4 weeks prior to the first dose of the experimental treatment, no evidence of new brain metastases or increase in size of pre-existing brain metastases as confirmed by repeat imaging) and do not require steroid therapy for at least 14 days prior to the first dose of the experimental treatment. This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable.
  • Presence of clinically uncontrolled pleural effusion or ascites (subjects may be recruited who do not require drainage of the effusion or who do not have a significant increase in the effusion after 3 days of cessation of drainage)
  • Patients with bone at risk of paraplegia
  • Known or suspected disease or history of such disease within the last 2 years (patients with vitiligo, psoriasis, alopecia areata or Graves' disease not requiring systemic treatment within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy may be enrolled)
  • Known to have active tuberculosis.
  • A history of allogeneic organ transplants and hematopoietic stem cell transplants is known
  • Known history of (HIV) infection (HIV-positive)
  • Known acute or chronic active virus (HBsAg-positive and HBVDNA viral load ≥200 IU/mL or ≥10\^3 copies/mL) or acute or chronic active virus (HCV antibody-positive and HCV RNA-positive)
  • Active syphilis infection requiring treatment
  • Suffer from interstitial lung disease requiring steroid hormone therapy
  • Serious infections that are active or poorly controlled clinically
  • Severe cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism); angina pectoris requiring treatment; symptomatic peripheral vascular disease; cardiac class 3 or 4 congestive heart failure; or uncontrolled ≥class 3 hypertension (diastolic blood pressure ≥100 mm Hg or systolic blood pressure ≥160 mm Hg) despite antihypertensive treatment
  • History of other primary within 5 years, except:

    1. malignancies that have been in complete remission for at least 2 years prior to enrolment and for which no other treatment was required during the study period.
    2. adequately treated non-melanoma skin cancer or malignant nevus with no evidence of disease recurrence.
    3. adequately treated carcinoma in situ without evidence of disease recurrence
  • Female patients who are pregnant or breastfeeding
  • Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory test values that may result in increased risk associated with study participation or administration of study medication, or interfere with the interpretation of study results, and that, in the investigator's judgement, classify the patient as ineligible for participation in this study.
Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    BRIO-I: Phase Ib Dose-Escalation Cohort

    Patients receive propranolol hydrochloride PO, sintilimab IV over 30 minutes of day 1 and chemotherapy IV. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

    Drug: Propranolol hydrochloride · Drug: Sintilimab · Drug: Chemotherapy

  • Experimental
    BRIO-II: Propranolol Group

    In the phase II stage, participants are randomly assigned in a 1:1 ratio to receive propranolol hydrochloride at the recommended phase II dose (RP2D) established during the phase Ib stage, in combination with sintilimab and platinum-based doublet chemotherapy.

    Drug: Sintilimab · Drug: Chemotherapy · Drug: Propranolol Hydrochloride R2PD

  • Placebo comparator
    BRIO-II: Standard Control Group

    In the phase II stage, participants are randomly assigned in a 1:1 ratio to receive propranolol hydrochloride matching placebo in combination with sintilimab and platinum-based doublet chemotherapy.

    Drug: Sintilimab · Drug: Chemotherapy · Drug: Propranolol hydrochloride matching placebo

Interventions

  • DrugPropranololStudies of PropranololPropranolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose-escalation: 10 mg PO BID, 10 mg PO TID, and 20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

    Also known as: Inderal

  • intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • DrugChemotherapy

    Platinum-based chemotherapy: For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • DrugPropranolol hydrochloride matching placebo

    20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

  • DrugPropranolol Hydrochloride R2PD

    20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs) (BRIO-I)

    AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.

    Time frame: 2 years

  2. Recommended phase II dose (RP2D) (BRIO-I)

    The recommended phase II dose (RP2D) of propranolol hydrochloride will be determined based on the incidence of DLTs across dose levels, overall safety and tolerability

    Time frame: 2 years

  3. Objective Response Rate (ORR) (BRIO-I)

    The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: 2 years

  4. Progression-free survival (PFS) (BRIO-II)

    Time from the randomization to the disease progression (PD) or death, whichever occurs first

    Time frame: 2 years

Secondary outcomes

  1. Overall survival (OS)

    Time from the beginning of intervention or randomization until death due to any cause. OS will be evaluated separately for the phase Ib and phase II cohorts.

    Time frame: 5 years

  2. Adverse events (AEs) (BRIO-II)

    AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.

    Time frame: 2 years

  3. Quality of life (QoL)

    Health-related quality of life will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire includes global health status/quality-of-life, functional, and symptom scales, each transformed to a score ranging from 0 to 100. Higher scores indicate better quality of life or functioning on the global health and functional scales, whereas higher symptom scores indicate greater symptom burden.

    Time frame: 2 years

  4. Objective Response Rate (ORR) (BRIO-II)

    The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: 2 years

  5. Disease Control Rate (DCR)

    Disease Control Rate (DCR) The proportion of patients with a complete response or partial response or stable disease to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). DCR will be evaluated separately for the phase Ib and phase II cohorts.

    Time frame: 2 years

  6. Duration of Response (DOR)

    DOR is defined as the time from the first documented complete response or partial response, to disease progression or death from any cause, whichever occurs first. DOR will be evaluated separately for the phase Ib and phase II cohorts.

    Time frame: 2 years

  7. Patient-Reported Emotional Distress

    Patient-reported emotional distress will be assessed using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety symptom. Each item is rated on a 4-point Likert scale: 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day). The total scores range from 0 to 27 for the PHQ-9 and from 0 to 21 for the GAD-7, with higher scores indicating greater symptom severity. Emotional distress is defined as PHQ-9 scores ≥5 and/or GAD-7 scores ≥5.

    Time frame: 2 years

  8. Patient-Reported Dispositional Optimism

    The dispositional optimism is evaluated by Life Orientation Test-Revised (LOT-R), Each item is rated on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree). LOT-R consists of 3 positively worded items and 3 negatively worded items, with a total score ranging from 0 to 24. Higher scores indicate greater dispositional optimism.

    Time frame: 2 years

  9. Patient-Reported Psychological Well-Being

    Psychological well-being will be assessed using the World Health Organization-Five Well-Being Index (WHO-5). The questionnaire consists of five items, each rated on a 6-point Likert scale ranging from 0 (at no time) to 5 (all of the time). The total raw score ranges from 0 to 25 and is multiplied by four to yield a standardized score ranging from 0 to 100. Higher scores indicate better psychological well-being.

    Time frame: 2 years

  10. Patient-Reported Sleep Quality

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) for sleep quality, Insomnia Severity Index (ISI) for insomnia severity. PSQI comprises seven components, each scored from 0 to 3. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. poor sleep quality is defined as a PSQI score ≥5 and/or an ISI score ≥8.

    Time frame: 2 years

  11. Patient-Reported Perceived Stress

    The perceived stress level is evaluated by the 10-item Perceived Stress Scale (PSS-10). Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with a total score ranging from 0 to 40. The PSS-10 consists of six positively worded items and four negatively worded items. Higher scores indicate greater perceived stress.

    Time frame: 2 years

  12. Patient-Reported Sleep Circadian preference

    Circadian preference will be assessed using the 5-item reduced Morningness-Eveningness Questionnaire (rMEQ). The total score ranges from 4 to 25, with higher scores indicating a stronger morningness preference.

    Time frame: 2 years

  13. Progression-free survival (PFS) (BRIO-I)

    Time from the beginning of intervention to the first disease progression (PD)

    Time frame: 2 years

Other outcomes

  1. Exploratory Peripheral Blood Biomarkers

    Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from peripheral blood. These analyses may include circulating stress-related hormones, immune cell profiles, molecular and metabolic biomarkers.

    Time frame: 2 years

  2. Exploratory Biomarkers in Tumor Microenvironment

    Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from tumor tissue. These analyses may include immune cell profiles, molecular and metabolic biomarkers.

    Time frame: 2 years

  3. Exploratory Biomarkers in Gut microbiota

    Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from stool samples. These analyses may include gut microbiota related composition.

    Time frame: 2 years

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2028, 47 months after the start.

Of 124 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's planned 47 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2025 → Oct 2028 and completion Dec 2026 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 7, 2023
StartActual
Nov 13, 2024
Primary completionEst.
Oct 31, 2028was Aug 2025
CompletionEst.
Dec 31, 2032was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 China)
  • Xiangya hospital of Central South University · Changsha, China
  • Hunan Cancer Hospital · Changsha, China
  • The Third Xiangya Hospital of Central South University · Changsha, China
Nov 19, 2026
Primary completion
Aug 31, 2025→Oct 31, 2028
Nov 19, 2026
Study completion
Dec 31, 2026→Dec 31, 2032
Nov 19, 2026
Enrollment
6→118
Nov 19, 2026
Eligibility
1 inclusion criterion removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • RemovedNo glucocorticoid therapy is required, or glucocorticoid therapy has been discontinued within 7 days prior to the first dose, or the glucocorticoid dosage has been stable and reduced to less than 10 mg/day of prednisone (or equivalent dose) within 7 days prior to the first dose
Exclusion criteria
  • EditedSevere asthma or chronic obstructive pulmonary disease (COPD)
Nov 19, 2026
Interventions
Added Drug: Propranolol hydrochloride matching placebo·Drug: Propranolol Hydrochloride R2PD. Arms added: BRIO-I: Phase Ib Dose-Escalation Cohort·BRIO-II: Propranolol Group·BRIO-II: Standard Control Group; arms removed: Propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy
Nov 19, 2026
Primary outcomes
2 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedObjective Response Rate (ORR) (BRIO-I)Time frame: 2 years
  • EditedAdverse events (AEs) (BRIO-I)Time frame: 2 years
  • AddedRecommended phase II dose (RP2D) (BRIO-I)Time frame: 2 years
  • AddedProgression-free survival (PFS) (BRIO-II)Time frame: 2 years
  • RemovedDisease Control Rate (DCR)Time frame: 2 years
Nov 19, 2026
Secondary outcomes
1 edited, 1 time frame changed, 13 added, 2 description edited
What changed in the outcomes
  • EditedProgression-free survival (PFS) (BRIO-I)Time frame: 3 years → 2 years
  • AddedAdverse events (AEs) (BRIO-II)Time frame: 2 years
  • AddedObjective Response Rate (ORR) (BRIO-II)Time frame: 2 years
  • AddedDisease Control Rate (DCR)Time frame: 2 years
  • AddedDuration of Response (DOR)Time frame: 2 years
  • AddedPatient-Reported Emotional DistressTime frame: 2 years
  • AddedPatient-Reported Dispositional OptimismTime frame: 2 years
  • AddedPatient-Reported Psychological Well-BeingTime frame: 2 years
  • AddedPatient-Reported Sleep QualityTime frame: 2 years
  • AddedPatient-Reported Perceived StressTime frame: 2 years
  • AddedPatient-Reported Sleep Circadian preferenceTime frame: 2 years
  • Time frameQuality of life (QoL)5 years → 2 years
  • DescriptionOverall survival (OS): how it is measured was reworded
  • DescriptionQuality of life (QoL): how it is measured was reworded
  • Addedother outcomeExploratory Peripheral Blood BiomarkersTime frame: 2 years
  • Addedother outcomeExploratory Biomarkers in Tumor MicroenvironmentTime frame: 2 years
  • Addedother outcomeExploratory Biomarkers in Gut microbiotaTime frame: 2 years
Nov 19, 2026
Design
Added Phase 2
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    3 sites added
    Show 3 added (3 China)
    • Xiangya hospital of Central South University · Changsha, China
    • Hunan Cancer Hospital · Changsha, China
    • The Third Xiangya Hospital of Central South University · Changsha, China
    Primary completion Aug 31, 2025→Oct 31, 2028
    Study completion Dec 31, 2026→Dec 31, 2032
    Enrollment 6→118
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • RemovedNo glucocorticoid therapy is required, or glucocorticoid therapy has been discontinued within 7 days prior to the first dose, or the glucocorticoid dosage has been stable and reduced to less than 10 mg/day of prednisone (or equivalent dose) within 7 days prior to the first dose
    Exclusion criteria
    • EditedSevere asthma or chronic obstructive pulmonary disease (COPD)
    Primary outcomes 2 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedObjective Response Rate (ORR) (BRIO-I)Time frame: 2 years
    • EditedAdverse events (AEs) (BRIO-I)Time frame: 2 years
    • AddedRecommended phase II dose (RP2D) (BRIO-I)Time frame: 2 years
    • AddedProgression-free survival (PFS) (BRIO-II)Time frame: 2 years
    • RemovedDisease Control Rate (DCR)Time frame: 2 years
    Secondary outcomes 1 edited, 1 time frame changed, 13 added, 2 description edited
    What changed in the outcomes
    • EditedProgression-free survival (PFS) (BRIO-I)Time frame: 3 years → 2 years
    • AddedAdverse events (AEs) (BRIO-II)Time frame: 2 years
    • AddedObjective Response Rate (ORR) (BRIO-II)Time frame: 2 years
    • AddedDisease Control Rate (DCR)Time frame: 2 years
    • AddedDuration of Response (DOR)Time frame: 2 years
    • AddedPatient-Reported Emotional DistressTime frame: 2 years
    • AddedPatient-Reported Dispositional OptimismTime frame: 2 years
    • AddedPatient-Reported Psychological Well-BeingTime frame: 2 years
    • AddedPatient-Reported Sleep QualityTime frame: 2 years
    • AddedPatient-Reported Perceived StressTime frame: 2 years
    • AddedPatient-Reported Sleep Circadian preferenceTime frame: 2 years
    • Time frameQuality of life (QoL)5 years → 2 years
    • DescriptionOverall survival (OS): how it is measured was reworded
    • DescriptionQuality of life (QoL): how it is measured was reworded
    • Addedother outcomeExploratory Peripheral Blood BiomarkersTime frame: 2 years
    • Addedother outcomeExploratory Biomarkers in Tumor MicroenvironmentTime frame: 2 years
    • Addedother outcomeExploratory Biomarkers in Gut microbiotaTime frame: 2 years
    Interventions Added Drug: Propranolol hydrochloride matching placebo·Drug: Propranolol Hydrochloride R2PD. Arms added: BRIO-I: Phase Ib Dose-Escalation Cohort·BRIO-II: Propranolol Group·BRIO-II: Standard Control Group; arms removed: Propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy
    Design Added Phase 2
    + 5 other changes: identifiers, verification date, responsible party, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05979818
Lead sponsor
Second Xiangya Hospital of Central South University
Responsible party
Fang Wu (Chief Physician, Professor, Second Xiangya Hospital of Central South University) — Principal investigator
First posted
Aug 7, 2023
Start date
Nov 13, 2024
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 19, 2026

Study contacts

Fang Wu, M.D, Ph.D
Contact
wufang4461@csu.edu.cn
+86 13574858332

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion